Brind.

AbCellera Biologics Inc. expects its growth rate to accelerate meaningfully.

1 report, 1 independent Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbCellera Biologics Inc. expects its growth rate to accelerate meaningfully.

How it developed

Newest first. Tap a step to see who reported it.
  1. An FDA decision influenced AbCellera's stock climb, related to the company's work advancing immune treatments.Sub-event
  2. AbCellera Biologics Inc. expects its growth rate to accelerate meaningfully.1 source

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Industry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue Forecasts Explore AbCellera Biologics's Fair Values from the Community and select yours AbCellera Bi